July 26, 2017
For 5 straight years, The Access Group has been recognized as one of the Top 100 Agencies by MM&M thanks to the company’s leading-edge work in managed markets.
Based on his speech to a joint session of Congress a few months ago, President Trump’s love/hate relationship with pharma will undoubtedly affect the care of many patients.
As health systems expand both in size and number, a corresponding trend has emerged for these organizations to increase their level of risk and clinical integration, with an emphasis on efficient and effective population health management.
There is one story as to why the American Health Care Act (AHCA) did not get through Congress but while there is only one story there are two very different meanings. The story goes that the AHCA would have resulted in 24M Americans losing health insurance while producing very little savings – about $700 per person per year. One translation – Americans would be better off with ObamaCare and therefore there was not enough support for the bill.
In the wake of the passing of the 21st Century Cures Act last December, Food and Drug Administration (FDA) released several guidance documents aimed at providing manufacturers with expanded regulatory latitude for product-related communications and promotion. With mounting pressure from industry and advocacy to expedite market approval of new therapies, FDA’s efforts signals a leaning to release or minimize regulatory restrictions that in the past have restricted the ability of manufacturers to promote products.
After attempting to repeal the Affordable Care Act more than 60 times in the last 5 years, Republican lawmakers have a chance to dismantle the health care law as early as the next few weeks. Last month, the House and Senate passed a bill that could be used to cut funds to key parts of the legislation. However, Republicans remain divided over how fast to move on repealing Obamacare without having a viable replacement plan ready to implement.